Effects of glucagon-like peptide 1 analogs in combination with insulin on myocardial infarct size in rats with type 2 diabetes mellitus

Abstract

AIMTo evaluate the effects of glucagon-like peptide-1 analogs (GLP-1a) combined with insulin on myocardial ischemia-reperfusion injury in diabetic rats.METHODSType 2 diabetes mellitus (T2DM) was induced in male Wistar rats with streptozotocin (65 mg/kg) and verified using an oral glucose tolerance test. After anesthesia, the left coronary artery was occluded for 40 min followed by 80 min reperfusion. Blood glucose level was measured during surgery. Rats were randomized into six groups as follows: (1) control rats; (2) insulin (0.1 U/kg) treated rats prior to ischemia; (3) insulin (0.1 U/kg) treated rats at reperfusion; (4) GLP-1a (140 mg/kg) treated rats prior to ischemia; (5) GLP-1a (140 mg/kg) treated rats at reperfusion; and (6) rats treated with GLP-1a (140 mg/kg) prior to ischemia plus insulin (0.1 U/kg) at reperfusion. Myocardial area at risk and infarct size was measured planimetrically using Evans blue and triphenyltetrazolium chloride staining, respectively.RESULTSThere was no significant difference in the myocardial area at risk among groups. Insulin treatment before ischemia resulted in a significant increase in infarct size (34.7% ± 3.4% vs 18.6% ± 3.1% in the control rats, P < 0.05). Post-ischemic administration of insulin or GLP-1a had no effect on infarct size. However, pre-ischemic administration of GLP-1a reduced infarct size to 12% ± 2.2% (P < 0.05). The maximal infarct size reduction was observed in the group treated with GLP-1a prior to ischemia and insulin at reperfusion (8% ± 1.6%, P < 0.05 vs the control and GLP-1a alone treated groups).CONCLUSIONGLP-1a pre-administration results in myocardial infarct size reduction in rats with T2DM. These effects are maximal in rats treated with GLP-1a pre-ischemia plus insulin at reperfusion.

Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors

“…An increase in the proliferation of β and α cells was noted in individual studies 7 . However, our earlier studies did not confirm the conclusion of an increased proliferation of pancreatic cells 8 . Taking into account the multi‐factorial effect of the above drugs on pancreatic cells, it would be interesting to evaluate the effects of drug‐combination therapy on β and α cells.…”

“…7 However, our earlier studies did not confirm the conclusion of an increased proliferation of pancreatic cells. 8 Taking into account the multi-factorial effect of the above drugs on pancreatic cells, it would be interesting to evaluate the effects of drug-combination therapy on β and α cells. It is known that gliclazide's mechanism of action is fundamentally different from other sulfonylureas.…”

Xuan Bi Tong Yu Fang Promotes Angiogenesis via VEGF-Notch1/Dll4 Pathway in Myocardial Ischemic Rats

“…CHD is the main cause of myocardial ischemia. With the improvement of living standards, the prevalence of myocardial ischemia in China is increasing annually and it has become a frequently [17][18][19][20]. Treatments based on traditional Chinese medicine have shown potential applications in myocardial ischemia treatment, and this has been reported in many studies.…”

Evaluation of cardioprotective effect of exenatide in type 2 diabetes mellitus and acute myocardial infarction in the clinic and experiment

“…Как было показано в наших более ранних публикациях отношение зоны некроза миокарда к зоне ишемии -наихудшее в группе, в которой введение инсулина было начато до индукции ишемии [31]. При введении препаратов перед реперфузией различия в соотношении размеров зоны некроза к зоне ишемии мирокарда меньше, однако в группах с добавлением эксенатида соотношение было лучшим, чем в группе инсулинотерапии, что сопровождалось также наиболее низкой вариабельностью гликемии и лучшей выживаемостью.…”